50 results about "Matrix Metalloprotease" patented technology

The invention discloses photocuring hydrogel capable of being combined with cytokines and used for tumor organoid culture and application, and belongs to the technical field of organoid culture. According to the invention, the hydrogel which can fix cells, can be combined with cell factors and can realize organoid recovery is developed through norbornene modified heparin, norbornene modified gelatin, sulfydryl four-arm polyethylene glycol, glucan, matrix metal protein peptidomimetic MMP and a photoinitiator. The hydrogel can be used for directly preparing organoids, heparin of various structures can be used, the cost is reduced, the modified heparin can bind factors or matrix protein and can controllably release the factors, the modified gelatin provides amino acid energy for collagen hydrolysate, and the hydrogel is formed by photocuring in a stepwise polymerization mode, is controllable in structure and can be used for preparing collagen collagen. The adjustable bionic modulus and the adjustable bionic stress relaxation are realized. The hydrogel disclosed by the invention can be used for culturing various organs, overcomes the problems of low repeatability, instability and the like in the prior art, and is suitable for the fields of tumor drug evaluation and the like.

The invention belongs to the technical field of cosmetics, and particularly relates to a natural-source composition with a function of inhibiting multiple types of matrix metalloproteinases of skin and application of the natural-source composition. The composition is prepared from the following components: herba cistanche powder, American ginseng powder, a red-knees herb extract and a creeping rostellularia herb extract. The composition has the effects of inhibiting expression of multiple types of matrix metalloproteinases in skin immortalized keratinocytes, improving elastin synthesis and inhibiting elastase decomposition, and has no obvious side effects. The composition disclosed by the invention can be used for preparing various cosmetics, functional foods and health-care products related to skin aging resistance, and has a wide application prospect.

Present disclosure relates to a fusion protein, and a preparation method therefor and the use thereof. The fusion protein comprises a GSDME mutant protein and a tumor cell-specific cell-penetrating peptide. In the GSDME mutant protein, a tumor-targeting effect is provided by mutating a sequence recognized by cysteine-aspartic proteases in GSDME protein into an amino acid sequence recognized by matrix metalloproteinase; and the in-vitro misfolding rate of GSDME protein is reduced by means of mutating cysteine to alanine, increasing the druggability of the protein. The fusion protein which has a tumor targeting property, penetrating property and tumor microenvironment-specific activation is constructed, which provides a new idea for the development of targeted anti-cancer drug.

The present invention is concerned with a protein oligomer comprising (i) at least two NC-1 monomers of collagen 18 or (ii) at least two endostatin domains of collagen 18 or (iii) at least two N-terminal peptides of the collagen 18 endostatin domain, for use in treating, ameliorating or preventing fibrosis or a fibrosis-associated disease, a vascular endothelial growth factor (VEGF)-related disease or a matrix metalloproteinase (MMP)-related disease. The invention further relates to the mentioned protein oligomer for use for detecting and / or diagnosing fibrosis or a fibrosis-associated disease, a vascular endothelial growth factor (VEGF)-related disease or a matrix metalloproteinase (MMP)-related disease.

The invention relates to the technical field of medicines, and provides application of pulsatilla saponin B4 in preparation of a medicine for treating osteoarthritis. The pulsatilla saponin B4 can obviously promote the expression of SOX9, which is an important cartilage specific transcription factor, and inhibit the expression of matrix metalloproteinase 13 and disintegrin and metalloproteinase 5 with platelet reaction protein motifs at the same time, thereby finally relieving the degradation of extracellular cartilage matrixes such as II-type collagen and aggregation proteoglycan. Therefore, the pulsatilla saponin B4 can inhibit cartilage degeneration and improve cartilage extracellular matrix metabolic disorder. After the pulsatilla saponin B4 is injected into the abdominal cavity of a mouse with osteoarthritis, the progress of the osteoarthritis is effectively relieved, the side effect is relatively small, and no obvious injury is caused to main organs. The pulsatilla saponin B4 is applied to treatment of osteoarthritis, new application of the pulsatilla saponin B4 is developed, and a new choice is provided for preparation of the medicine for treating osteoarthritis.

Hydantoin based compounds useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.

The present invention provides a method for activating matrix metalloproteinase 1 (proMMP-1) to matrix metalloproteinase 1 (MMP-1), comprising: a first incubation in which proMMP-1 is incubated in a solution containing an imidazole and / or an imidazolyl group-containing compound; and a second incubation in which the proMMP-1 subjected to the first incubation is incubated in a solution containing Ca < 2 + >. The invention also provides a kit for activating proMMP-1 into MMP-1, which comprises proMMP-1 or a solution containing proMMP-1, imidazole and / or a compound containing imidazolyl, or a solution containing imidazole and / or a compound containing imidazolyl, and a substance capable of generating calcium ions (Ca < 2 + >) or a solution containing Ca < 2 + >, which are packaged respectively. The invention also provides application of the proMMP-1 or a solution containing the proMMP-1, imidazole and / or a compound containing an imidazolyl group, or a solution containing the imidazole and / or the compound containing the imidazolyl group, and a substance capable of generating calcium ions (Ca < 2 + >) or a solution containing Ca < 2 + > in preparation of a kit for activating the proMMP-1 into the MMP-1.

A composition for inhibiting functions of various types of matrix metalloproteinases in skin and a use thereof. The composition comprises one or more of the following components: epigallocatechin gallate (EGCG), dihydroquercetin, sugarcane polyphenol, coix seed powder, ginseng, or galangal. The composition has the effects of inhibiting expression of various types of matrix metalloproteinases in skin fibroblasts, inhibiting activity of matrix metalloproteinases, improving collagen content, and inhibiting elastase, and does not have obvious side effects. The composition can be used for preparing various cosmetics, functional foods and health care products related to skin aging resistance, and has a wide application prospect.

Provided is an oral composition comprising an L-ascorbic acid dl-α-tocopherol phosphoric acid diester alkali metal salt. The composition according to the present disclosure is capable of suppressing disruption of the oral mucosal epithelial barrier function and / or inhibiting the activity of matrix metalloproteinases (MMPs). Thus, the composition according to the present disclosure is capable of preventing the onset of periodontal disease and / or suppressing the progression of periodontal disease.

The present invention provides specific matrix metalloproteinase (MMP) polypeptide inhibitors and uses thereof in treating MMP-related diseases, in particular cancer, such as breast cancer and glioblastoma.

The application provides an engineered exosome loaded with a CD63 transmembrane domain-matrix metalloproteinase fusion protein and a preparation method and application thereof. The engineered exosome is secreted by a genetically engineered mesenchymal stem cell, has a CD63 derived transmembrane domain anchored on the membrane, and has a matrix metalloproteinase (MMP) loaded on the inner side of the membrane. The fusion protein comprises, from N-terminus to C-terminus, a fourth transmembrane domain and a C-terminal cytoplasmic tail of a human CD63 protein, a flexible linker peptide, and a human MMP without a natural signal peptide. The application realizes efficient and directional loading of MMPs by using a natural biological generation path of the exosome, shields the inhibition of MMPs by metalloproteinase tissue inhibitors in a scar tissue by using the membrane of the exosome, realizes specific activation of MMPs in a target cell, degrades abnormally deposited collagen, adjusts the ratio of type I and type III collagens, and plays an anti-fibrosis and anti-scar formation role. The application also provides a preparation method of the engineered exosome and application thereof in preparation of a medicine for preventing or treating pathological scars.

The present invention belongs to the field of biomedicine technology, and more specifically, to a magnetic probe and its application in the preparation and detection of matrix metalloproteinases. The present invention provides a magnetic probe and its application in the preparation and detection of matrix metalloproteinases, the purpose of which is to utilize the hydrolysis characteristics of matrix metalloproteinases to identify specific oligopeptide sequences and cut them, prepare functionalized signal probes, and combine magnetic separation technology and commercial test strips to solve the problems of high cost, low detection sensitivity and narrow scope of application of the existing technology. The present invention utilizes the high specificity of protease hydrolysis and the high sensitivity of the test strips to the target probe to achieve sensitive detection of MMP-1, with a visual detection limit of 65.5 pg / mL, which has good anti-interference and sensitivity in the application of biological sample matrices.

To provide an isolated polypeptide comprising a tandem substrate, an activatable antibody that specifically binds to a target and a production method therefor, and methods for using these in a variety of therapeutic, diagnostic and prophylactic indications.SOLUTION: The invention provides polypeptides that include at least a first cleavable moiety (CM1) that is a substrate for at least one matrix metalloprotease (MMP) and at least a second cleavable moiety (CM2) that is a substrate for at least one serine protease (SP) or at least one cysteine protease (CP).SELECTED DRAWING: Figure 1

The application belongs to the technical field of regenerative medicine, and particularly relates to an ASP / BFP-1 sustained-release nanofiber membrane and a preparation method and application thereof. In the initial stage of bone repair, matrix metalloproteinase-2 (MMP-2) secreted by a large number of stem cells can effectively degrade gelatin and polylysine in the nanofiber membrane coating, so as to sequentially release aspirin and bone formation peptide-1 in the drug-loaded coating. The released aspirin can control inflammation, and the bone formation peptide-1 can enhance the osteogenic potential of stem cells and guide bone tissue regeneration.

To identify new substrates for proteases and use these substrates for a variety of therapeutic, diagnostic and prophylactic applications.SOLUTION: The invention relates generally to polypeptides that include a cleavable moiety that is a substrate for at least one matrix metalloprotease (MMP), to activatable antibodies and other large molecules that include the cleavable moiety that is a substrate for at least one MMP protease, and to methods of making these polypeptides that include a cleavable moiety that is a substrate for at least one MMP protease and using them for a variety of therapeutic, diagnostic and prophylactic applications.SELECTED DRAWING: Figure 1A

The present invention provides a high-quality lychee juice processing method and product thereof. The content of oxygen and carbon dioxide in lychee juice and the ratio of the two are controlled to inhibit the growth of microorganisms in the lychee juice; the non-uniform distribution of sugar in lychee aril is used to prepare low-sugar lychee juice; proanthocyanidins are extracted from lychee shells and added to lychee juice to inhibit the hydrolysis of collagen and connective tissue by matrix metalloproteinases.

The invention discloses application of L-histidine in treatment of osteoarthritis, and belongs to the technical field of medicine application. Through verification of cell experiments and animal experiments, it is found that L-histidine can improve osteophyte hyperplasia, meanwhile, expression of matrix metalloproteinases MMP13 and MMP3 and expression of proteoglycan ADAMTS5 can be reduced, expression of SOX9, Aggrecan and COL2A1 in extracellular matrixes can be effectively increased, and therefore the effect of treating osteoarthritis is achieved; the invention clarifies the influence and action mechanism of L-histidine on osteoarthritis, and provides a new thought for clinical treatment of osteoarthritis.

The invention relates to an application of GalvoC in preparation of a product for resisting skin aging and / or promoting skin repair. A large number of experiments prove that the GalivoC has good safety in preparation of products for resisting skin aging and / or promoting skin repair, and has great clinical application prospects and values, specifically, the GalivoC can activate expression of SIRT1 protein, significantly inhibit activity of matrix metalloproteinase MMP1, and can be used for preparing anti-aging products for skin and / or promoting skin repair, so that the GalivoC can be used for preparing anti-aging products for skin and / or promoting skin repair. The synthesis of collagen type I and collagen type III is promoted, so that the reduction of the content of various collagens in skin keratinocytes caused by UV light aging stimulation is improved, the healing ability of cell scratches is promoted, and the effect is superior to that of the existing activator resveratrol.

The invention relates generally to cleavable polypeptides, method of producing a cleavable moiety (CM) containing polypeptide by culturing a cell under conditions that lead to expression of the polypeptide, methods of manufacturing a cleavable moiety (CM) containing polypeptide by culturing a cell comprising a nucleic acid construct that encodes the cleavable polypeptide to express the cleavable polypeptide, and recovering the cleavable polypeptide, nucleic acids encoding the cleavable polypeptides, and vectors including the nucleic acids encoding the cleavable polypeptides.

Hydantoin based compounds useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.

Isolated polypeptides that include a cleavable moiety that is a substrate for at least one protease (e.g., MT-SP1 and / or an MMP) and isolated polypeptides that include a substrate that has a first cleavable moiety cleavable by a first protease and a second cleavable moiety cleavable by a second protease are disclosed. Activatable molecules including the isolated polypeptides are disclosed. Methods of making and using the isolated polypeptides and activatable molecules including the isolated polypeptides in a variety of therapeutic, diagnostic, and prophylactic applications are disclosed.

The invention discloses a matrix metalloproteinase MMP2 gene and application of dsRNA of the matrix metalloproteinase MMP2 gene in prevention and treatment of ladybird beetles. The dsRNA for synthesizing the matrix metalloproteinase gene MMP2 of the ladybird is injected into the body of the ladybird, so that the MMP2 gene of the ladybird can be specifically silenced, the ecdysis of the larva of the ladybird can be inhibited, the metamorphosis and development of the larva fail, then the individual death is caused, and the purpose of biological control is achieved; the method has the advantages of specificity, high efficiency and environmental protection in pest control, is a novel green pollution-free ladybird prevention and control technology, and shows a huge application prospect in prevention and control of ladybird.

The invention relates to the field of biological pharmacy, in particular to application of a regulatory factor inhibitor in preparation of a medicine for treating scapulohumeral periarthritis, and the regulatory factor inhibitor is used for inhibiting expression of interleukin 6 and / or inhibiting expression of matrix metalloproteinase 2 and matrix metalloproteinase 9. By inhibiting the expression of the regulatory factors, the activity of M1 type macrophages is inhibited, the activity of M2 type macrophages is not influenced, the development of inflammation is inhibited through an immune system, and the anti-inflammatory effect is improved.

The invention relates to the field of medicine, in particular to a biomarker for diagnosis and prognosis evaluation of ventricular arrhythmia of a patient with dilated cardiomyopathy (DCM) and application of the biomarker. Matrix metalloproteinase-9 (MMP-9), 5-hydroxytryptamine (5-HT), noradrenaline (NE) and acetylcholine (ACh) are screened to serve as a biomarker combination, and by measuring the levels of MMP-9, 5-HT, NE and ACh in plasma, whether a DCM patient is accompanied with ventricular arrhythmia or not can be effectively recognized, the severity of the condition of the patient is evaluated, and the prognosis risk of the patient is predicted. The synergistic effect of MMP-9, 5-HT, NE and ACh can complement the defects of a single index, the diagnosis efficiency is improved, particularly, high specificity is achieved for ventricular arrhythmia, and an important basis is provided for risk stratification and individualized treatment of DCM patients.

The present invention relates generally to polypeptides comprising at least a first cleavable moiety (CM1) as a substrate for at least one matrix metalloproteinase (MMP) and at least a second cleavable moiety (CM2) as a substrate for at least one serine protease (SP) or at least one cysteine protease (CP); to activatable antibodies and other larger molecules comprising these polypeptides comprising at least CM1 as a substrate for at least one MMP protease and at least CM2 as a substrate for at least one SP protease or at least one cysteine protease (CP); the present invention relates to polypeptides comprising at least CM1 as a substrate for at least one MMP protease and at least CM2 as a substrate for at least one SP protease or at least one cysteine protease (CP), and to methods of making and using these polypeptides in a variety of therapeutic, diagnostic and prophylactic indications.

Compositions and methods for cosmetic applications are disclosed. The composition can contain ascorbic acid tetrahexyldecanol ester, phyllanthus emblica fruit extract, tocopherol and ascorbic acid. The composition may also comprise a plant amino acid. An effective amount of the composition may be applied to the skin to stimulate collagen production and lysyl oxidase activity, inhibit tyrosinase, inhibit melanogenesis and / or COX-1 activity, and inhibit matrix metalloproteinase activity in the skin.

Disclosed is an in vitro method for assessing whether a human patient suffering from periodontitis has mild periodontitis or advanced periodontitis. The method is based on the insight to determine a selection of three biomarker proteins. Accordingly, in a sample of saliva a patient suffering from periodontitis, the concentrations are measured of the proteins Interleukin-1β (IL-1β), Matrix metalloproteinase-9 (MMP-9) and at least one of the proteins: Interleukin-6 (IL-6), and Matrix metalloproteinase-3 (MMP-3). Based on the concentrations as measured, a value is determined reflecting the joint concentrations for said proteins. This value is compared with a threshold value reflecting in the same manner the joint concentrations associated with advanced periodontitis. The comparison allows assessing whether the testing value is indicative of the presence of advanced periodontitis or of mild periodontitis in said patient. Thereby, typically, a testing value reflecting a joint concentration below the joint concentration reflected by the threshold value is indicative for mild periodontitis in said patient, and a testing value reflecting a joint concentration at or above the joint concentration reflected by the threshold value, is indicative for advanced periodontitis in said patient.

An in vitro method for assessing whether a human patient has gingivitis is disclosed. The method is based on the insight of determining biomarker proteins. Therefore, in a saliva sample of a patient suffering from gingivitis, the concentration of a specific protein combination is measured. One such combination is alpha-1-acid glycoprotein (A1AGP) and at least one of the following: matrix metalloproteinase-8 (MMP8), matrix metalloproteinase-9 (MMP9), hepatocyte growth factor (HGF), hemoglobin beta subunit (Hb-β) and S100 calcium binding protein A8 (S100A8). Based on the measured concentration, a value reflecting the combined concentration of the protein is determined. The value is compared with a threshold value, which reflects the combined concentration associated with gingivitis in the same manner. Comparison allows an assessment of whether a test value indicates the presence of gingivitis in the patient. Thus, generally, a test value reflecting a combined concentration lower than the combined concentration reflected by the threshold indicates the absence of gingivitis in the patient, and a test value reflecting a combined concentration equal to or higher than the combined concentration reflected by the threshold indicates that the patient suffers from gingivitis.

The present disclosure generally relates to compositions that inhibit matrix metalloproteinases (MMPs). These compositions may be particularly useful in treating periodontal disease and skin wrinkling. The compositions can be prepared as a topical formulation, ointment, mouthwash, or packaged in a syringe.

The invention belongs to the field of biological medicine, and particularly relates to double-stranded oligonucleotide of a targeted MMP-7 gene and application of the double-stranded oligonucleotide. Specifically, provided are a double-stranded oligonucleotide agent or a salt, conjugate, composition thereof for inhibiting the expression of matrix metalloproteinase 7 (MMP-7) wherein the double-stranded oligonucleotide agent comprises one sense strand and one antisense strand forming a double-stranded region; wherein the antisense strand sequence comprises at least 15 contiguous nucleotides of the sequence shown in any one of SEQ ID NO: 1-85 and the difference is not greater than 3 nucleotides, and / or the sense strand sequence comprises at least 15 contiguous nucleotides of the sequence shown in any one of SEQ ID NO: 86-170 and the difference is not greater than 3 nucleotides. The double-strand oligonucleotide agent for inhibiting the expression of the MMP-7 or the salt thereof disclosed by the invention can obviously inhibit the expression of the MMP-7, and can be used for preventing and / or treating MMP-7 gene mediated diseases or symptoms.